Chitinase-3 like-protein-1 function and its role in diseases

Area of Science:

• Biochemistry
• Molecular Biology
• Immunology

Background:

• Non-enzymatic chitinase-3 like-protein-1 (CHI3L1) is a secreted protein belonging to glycoside hydrolase family 18.
• It interacts with extracellular matrix components and is modulated by various physiological and pathological factors.
• CHI3L1 is produced by diverse cell types, including immune cells, structural cells, and tumor cells.

Purpose of the Study:

• To review the multifaceted roles and underlying mechanisms of CHI3L1 in oncogenesis and disease pathogenesis.
• To explore the potential of CHI3L1 as a therapeutic target in various diseases, particularly cancer and inflammatory conditions.
• To discuss current and future investigational strategies for CHI3L1-targeted therapies.

Main Methods:

• Literature review of studies investigating CHI3L1 function, regulation, and association with diseases.
• Analysis of CHI3L1 expression patterns in normal tissues, disease states, and tumor models.
• Examination of identified CHI3L1 receptors and downstream signaling pathways involved in cancer progression.

Main Results:

• CHI3L1 is implicated in tissue injury, inflammation, repair, and remodeling, and is associated with numerous diseases like asthma, arthritis, and cancer.
• Overexpression of CHI3L1 is observed in various human cancers and animal tumor models, correlating with tumor growth, invasion, and metastasis.
• CHI3L1 signaling promotes cancer cell proliferation, angiogenesis, and modulates the tumor microenvironment, including immune cell activity.

Conclusions:

• CHI3L1 is a key mediator in oncogenesis and disease pathogenesis, acting through interactions with its receptors and influencing cellular processes.
• Targeted therapies focusing on CHI3L1 are emerging as promising treatment strategies for tumors such as glioma and colon cancer, as well as for rheumatoid arthritis.
• Further research into CHI3L1 mechanisms and targeted interventions holds significant potential for advancing therapeutic options in oncology and beyond.